


PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07D 209/42, 401/06, 401/12, A61K 31/40, 31/44, A61P 29/00	A1	(11) International Publication Number: WO 00/46197 (43) International Publication Date: 10 August 2000 (10.08.00)
(21) International Application Number: PCT/GB00/00271		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 31 January 2000 (31.01.00)		
(30) Priority Data: 9902453.1 5 February 1999 (05.02.99) GB		
(71) Applicant (<i>for all designated States except US</i>): ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).		
(72) Inventors; and		Published
(75) Inventors/Applicants (<i>for US only</i>): FAULL, Alan, Wellington [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). KETTLE, Jason [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).		<i>With international search report.</i>
(74) Agent: BRYANT, Tracey; Global Intellectual Property, AstraZeneca UK Limited, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).		

(54) Title: INDOLE DERIVATIVES AND THEIR USE AS MCP-1 RECEPTOR ANTAGONISTS



(57) Abstract

A compound of formula (I) wherein X is CH_2 or SO_2 ; R^1 is an optionally substituted aryl or heteroaryl ring; R^4 is a group $\text{C}(\text{O})\text{NR}^{15}\text{R}^{16}$ or a group $(\text{CH}_2)_n\text{R}^{17}$; where R^{15} , R^{16} and R^{17} are specified groups, and R^2 , R^3 , R^5 , R^6 and R^7 are specified organic groups; or a pharmaceutically acceptable salt, *in vivo* hydrolysable ester, or amide of the compound of formula (I). These compounds are useful in therapy, in particular of inflammatory disease, and methods of producing them as well as pharmaceutical compositions containing them are also described and claimed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INDOLE DERIVATIVES AND THEIR USE AS MCP-1 RECEPTOR ANTAGONISTS

The present invention relates to chemical compounds, to their production as well as to pharmaceutical compositions containing them as well as to their use in therapy, in particular
5 of inflammatory disease.

MCP-1 is a member of the chemokine family of pro-inflammatory cytokines which mediate leukocyte chemotaxis and activation. MCP-1 is a C-C chemokine which is one of the most potent and selective T-cell and monocyte chemoattractant and activating agents known. MCP-1 has been implicated in the pathophysiology of a large number of inflammatory
10 diseases including rheumatoid arthritis, glomerular nephritides, lung fibrosis, restenosis (International Patent Application WO 94/09128), alveolitis (Jones et al., 1992, *J. Immunol.*, 149, 2147) and asthma. Other disease areas where MCP-1 is thought to play a part in their pathology are atherosclerosis (e.g. Koch et al., 1992, *J. Clin. Invest.*, 90, 772 -779), psoriasis (Deleuran et al., 1996, *J. Dermatological Science*, 13, 228-236), delayed-type
15 hypersensitivity reactions of the skin, inflammatory bowel disease (Grimm et al., 1996, *J. Leukocyte Biol.*, 59, 804-812), multiple sclerosis and brain trauma (Berman et al. 1996, *J. Immunol.*, 156, 3017-3023). An MCP-1 inhibitor may also be useful to treat stroke, reperfusion injury, ischemia, myocardial infarction and transplant rejection.

MCP-1 acts through the MCP-1 receptor (also known as the CCR2 receptor). MCP-2
20 and MCP-3 may also act, at least in part, through the MCP-1 receptor. Therefore in this specification, when reference is made to "inhibition or antagonism of MCP-1" or "MCP-1 mediated effects" this includes inhibition or antagonism of MCP-2 and/or MCP-3 mediated effects when MCP-2 and/or MCP-3 are acting through the MCP-1 receptor.


Copending International Patent Application Nos. PCT/GB98/02340 and
25 PCT/GB98/02341 describe and claim groups of compounds based upon the indole ring structure which are inhibitors of MCP-1 and therefore have applications in therapy.

The use of certain indole derivatives as NMDA antagonists is described in USP5051442, WO9312780, EP-483881. Other indoles and their use as inhibitors of leukotriene biosynthesis is described in for example, EP-A- 275-667.

The applicants have found a particular substitution on the indole ring produces advantageous results when used therapeutically as inhibitors of MCP-1.

According to the present invention there is provided a compound of formula (I)


5



(I)

X is CH₂ or SO₂

10 R¹ is an optionally substituted aryl or heteroaryl ring;
 R² is carboxy, cyano, -C(O)CH₂OH, -CONHR⁸, -SO₂NHR⁹, tetrazol-5-yl, SO₃H, or a group of formula (VI)



(VI)

15 where R⁸ is selected from hydrogen, alkyl, aryl, cyano, hydroxy, -SO₂R¹² where R¹² is alkyl, aryl, heteroaryl, or haloalkyl, or R⁸ is a group-(CHR¹³)_r-COOH where r is an integer of 1-3 and each R¹³ group is independently selected from hydrogen or alkyl; R⁹ is hydrogen, alkyl, optionally substituted aryl such as optionally substituted phenyl or optionally substituted heteroaryl such as 5 or 6 membered heteroaryl groups, or a group COR¹⁴ where R¹⁴ is alkyl, 20 aryl, heteroaryl or haloalkyl; R¹⁰ and R¹¹ are independently selected from hydrogen or alkyl, particularly C₁₋₄ alkyl;

R³ is hydrogen; a functional group, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocycll, optionally substituted alkoxy, optionally substituted aralkyl, optionally substituted aralkyloxy, optionally substituted cycloalkyl;

5 R⁴ is a group C(O)NR¹⁵R¹⁶ or a group (CH₂)_tR¹⁷ ;
where R¹⁵ and R¹⁶ are independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl or optionally substituted heterocycll provided that R¹⁵ and R¹⁶ are not both hydrogen, or R¹⁵ and R¹⁶ together with the nitrogen atom to which they are attached form an optionally

10 substituted heterocyclic ring which optionally contains further heteroatoms;

R¹⁷ is selected from NR¹⁸R¹⁹, OR²⁰ or S(O)_sR²¹

where R¹⁸ and R¹⁹ are independently selected from hydrogen, optionally substituted hydrocarbyl or optionally substituted heterocycll, or R¹⁸ and R¹⁹ together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring which

15 optionally contains further heteroatoms;

R²⁰ is substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl or optionally substituted heterocycll,

R²¹ is optionally substituted hydrocarbyl or optionally substituted heterocycll,
s is 0, 1 or 2 and t is an integer of from 1-4;

20 R⁵, R⁶ and R⁷ are independently selected from hydrogen, a functional group or an optionally substituted hydrocarbyl groups or optionally substituted heterocycll groups.

In addition, the invention provides a pharmaceutically acceptable salt, *in vivo* hydrolysable ester, or amide of the compound of formula (I).

Compounds of formula (I) are inhibitors of monocyte chemoattractant protein-1. In
25 addition, they appear to inhibit RANTES induced chemotaxis. RANTES is another chemokine from the same family as MCP-1, with a similar biological profile, but acting through the CCR1 receptor. As a result, these compounds can be used to treat disease mediated by these agents, in particular inflammatory disease. Thus the invention further provides a compound of formula (I) for use in the treatment of inflammatory disease.

30 In this specification the term 'alkyl' when used either alone or as a suffix includes straight chained, branched structures. These groups may contain up to 10, preferably up to 6 and more preferably up to 4 carbon atoms. Similarly the terms "alkenyl" and "alkynyl" refer

to unsaturated straight or branched structures containing for example from 2 to 10, preferably from 2 to 6 carbon atoms. Cyclic moieties such as cycloalkyl, cycloalkenyl and cycloalkynyl are similar in nature but have at least 3 carbon atoms. Terms such as "alkoxy" comprise alkyl groups as is understood in the art.

5 The term "halo" includes fluoro, chloro, bromo and iodo. References to aryl groups include aromatic carbocyclic groups such as phenyl and naphthyl. The term "heterocyclyl" or "heterocyclic" includes aromatic or non-aromatic rings, for example containing from 4 to 20, suitably from 5 to 8 ring atoms, at least one of which is a heteroatom such as oxygen, sulphur or nitrogen. Nitrogen heteroatoms may be substituted for example with hydrogen or
10 hydrocarbyl depending on the available bonds. Sulphur atoms may be in the form of S, S(O) or S(O)₂.

Examples of such groups include furyl, thienyl, pyrrolyl, pyrrolidinyl, imidazolyl, triazolyl, thiazolyl, tetrazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, quinolinyl, isoquinolinyl, quinoxalinyl, benzothiazolyl, benzoxazolyl,
15 benzothienyl or benzofuryl.

"Heteroaryl" refers to those groups described above which have an aromatic character. The term "aralkyl" refers to aryl substituted alkyl groups such as benzyl.

Other expressions used in the specification include "hydrocarbyl" which refers to any structure comprising carbon and hydrogen atoms. For example, these may be alkyl, alkenyl,
20 alkynyl, aryl, heterocyclyl, alkoxy, aralkyl, cycloalkyl, cycloalkenyl or cycloalkynyl.

The term "functional group" refers to reactive substituents. They may comprise electron-donating or electron-withdrawing. Examples of such groups include halo, cyano, nitro, C(O)_nR²², OR²², S(O)_mR²², NR²³R²⁴, C(O)NR²³R²⁴, OC(O)NR²³R²⁴, -NR²³C(O)_nR²², -NR²²CONR²³R²⁴, -N=CR²²R²³, S(O)_mNR²³R²⁴ or -NR²³S(O)_mR²² where R²², R²³ and R²⁴ are
25 independently selected from hydrogen or optionally substituted hydrocarbyl, or R²³ and R²⁴ together form an optionally substituted heterocyclic ring as defined above, which optionally contains further heteroatoms such as sulphur, S(O), SO₂, oxygen and nitrogen, n is an integer of 1 or 2, m is an integer of 1-2.

Suitable optional substituents for hydrocarbyl or groups R²², R²³ and R²⁴ include halo, perhaloalkyl such as trifluoromethyl, mercapto, hydroxy, carboxy, alkoxy, heteroaryl, heteroaryloxy, alkenyloxy, alkynyoxy, alkoxyalkoxy, aryloxy (where the aryl group may be

substituted by halo, nitro, or hydroxy), cyano, nitro, amino, mono- or di-alkyl amino, oximino or $S(O)_m R^{25}$ where m' is 1 or 2 and R^{25} is alkyl.

Where R^{23} and R^{24} form a heterocyclic group, this may be optionally substituted by hydrocarbyl such as alkyl as well as those substituents listed above for hydrocarbyl groups.


5 Suitable substituents for hydrocarbyl or heterocyclic groups R^5 , R^6 and R^7 include those listed above for R^{22} , R^{23} and R^{24} .

Suitably R^1 is an optionally substituted phenyl, pyridyl, naphthyl, furyl or thienyl ring, and in particular is a substituted phenyl or pyridyl ring.

Suitable optional substituents for R^1 in formula (I) include alkyl, alkenyl, alkynyl,
 10 halo, haloalkyl including perhaloalkyl such as trifluoromethyl, mercapto, alkoxy, haloalkoxy, alkenyloxy, alkynyoxy, hydroxyalkoxy, alkoxyalkoxy, alkanoyl, alkanoyloxy, cyano, nitro, amino, mono- or di-alkyl amino, oximino, sulphonamido, carbamoyl, mono or dialkylcarbamoyl or $S(O)_m R^{26}$ where m is as defined above and R^{26} is hydrocarbyl.

Particular examples of substituents R^5 , R^6 and R^7 include hydrogen, hydroxy, halo,
 15 optionally substituted alkyl such as aralkyl, carboxyalkyl or the amide derivative thereof; alkoxy; aryloxy; aralkyloxy; or an amino group which is optionally substituted with alkyl, aryl or aralkyl. A specific functional group which is suitable for R^5 , R^6 and/or R^7 is a group of sub-formula (IV).

20



(IV)

Particular examples of groups R^5 , R^6 and R^7 are hydrogen, hydroxy, halo or alkoxy.
 In particular R^6 and R^7 are hydrogen. R^5 may be hydrogen but in addition is suitably a small
 25 substituent such as hydroxy, halo or methoxy.


Particular substituents for R^1 include trifluoromethyl, C_{1-4} alkyl, halo, trifluoromethoxy, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, nitro, carbamoyl, C_{1-4} alkoxycarbonyl, C_{1-4} alkylsulphanyl, C_{1-4} alkylsulphinyl, C_{1-4} alkylsulphonyl, sulphonamido, carbamoyl C_{1-4} alkyl, $N-(C_{1-4}\text{alkyl})\text{carbamoyl}C_{1-4}\text{alkyl}$, $N-(C_{1-4}\text{alkyl})_2\text{carbamoyl}-C_{1-4}\text{alkyl}$,
 30 hydroxy C_{1-4} alkyl or C_{1-4} alkoxy C_{1-4} alkyl.

Additionally or alternatively, two such substituents together may form a divalent radical of the formula -O(CH₂)₁₋₄O- attached to adjacent carbon atoms on the R¹ ring.

Preferred substituents for R¹ are one or more non-polar substituents such as halo.

In particular, R¹ is substituted by one or more halo groups, in particular chlorine. A 5 particular example of an R¹ group is 3,4-dichlorophenyl, 3-fluoro-4-chlorophenyl, 3-chloro-4-fluorophenyl or 2,3-dichloropyrid-5-yl.

Examples of groups R² include carboxy; cyano; tetrazol-5-yl; SO₃H; -CONHR⁸ where R⁸ is selected from cyano, hydroxy, -SO₂R¹² where R¹² is alkyl such as C₁₋₄ alkyl, aryl such as phenyl, heteroaryl or trifluoromethyl, or R⁸ is a group-(CHR¹⁰),-COOH where r is an integer of 10 1-3 and each R¹⁰ group is independently selected from hydrogen or alkyl such as C₁₋₄ alkyl; or R² is a group -SO₂NHR⁹ where R⁹ is an optionally substituted phenyl or an optionally substituted 5 or 6 membered heteroaryl group, or a group COR¹⁴ where R¹⁴ is alkyl such as C₁₋₄ alkyl, aryl such as phenyl, heteroaryl or trifluoromethyl, or R² is a group of formula (VI)



15

(VI)

where R¹⁰ and R¹¹ are independently selected from hydrogen or alkyl, particularly C₁₋₄ alkyl.

Preferably R² is carboxy or a pharmaceutically acceptable salt or ester thereof.

Suitable groups R³ include hydrogen, fluoro, chloro, bromo, iodo, methyl, cyano, trifluoromethyl, hydroxymethyl, alkoxyalkyl such as C₁₋₄ alkoxyalkyl, methoxy, benzyloxy, 20 carboxyalkoxy such as carboxymethoxy, methylsulphonyl, methylsulphinyl, methylsulphonyl or carboxyC₃₋₆cycloalkyl, -(CHR²⁷),-NR²⁸R²⁹ (where r is 0-2, each R²⁷ is independently hydrogen or alkyl, in particular C₁₋₄ alkyl, R²⁸ and R²⁹ are independently selected from H and C₁₋₄ alkyl or R²⁸ and R²⁹ together with the nitrogen to which they are attached form a 5 or 6 membered ring optionally containing one further heteroatom selected from O, N, S, S(O) or 25 SO₂. Suitably R²⁸ and R²⁹ together form a heterocyclic ring such as morpholino or piperazinyl.

Other such groups R³ include optionally substituted aryl groups, such as optionally substituted phenyl or naphthyl group. Suitable substituents for phenyl groups R³ include

one or more groups selected from chlorine, fluorine, methyl, trifluoromethyl, trifluoromethoxy, amino, formyl, phenyl, methoxy, phenoxy or phenyl.

R³ may comprise a range of substituents as listed above, in particular, hydrogen or a small substituent group such as C₁₋₄alkyl in particular methyl, or trifluoromethyl, and is 5 preferably hydrogen.

Suitable substituents for hydrocarbyl and heterocyclic groups R¹⁵, R¹⁶, R¹⁸, R¹⁹, R²⁰ and R²¹ as they appear in the definition of R⁴ include those listed above in relation to R²², R²³ and R²⁴.

Examples of R⁴ are groups C(O)NR¹⁵R¹⁶ where one of R¹⁵ or R¹⁶ is hydrogen or alkyl 10 such as methyl, and the other is optionally substituted heterocyclyl or optionally substituted alkyl such as C₁₋₂ alkyl in particular methyl, or R¹⁵ and R¹⁶ together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring which optionally contains further heteroatoms. Suitable optional substituents for heterocyclic groups R¹⁵ or R¹⁶ in this case are alkyl groups such as methyl, or oxo groups. Suitable optional substituents 15 for alkyl groups R¹⁵ and R¹⁶ include one or more groups selected from amino ; mono- or di-alkyl amino; carboxy; heterocyclyl optionally substituted with for example an alkyl groups such as methyl or an oxo group; or a group NHSO₂R³⁰ where R³⁰ is alkyl such as methyl.

A preferred group for R⁴ is a group C(O)NR¹⁵R¹⁶ where one of R¹⁵ or R¹⁶ is hydrogen and the other is heterocyclyl or alkyl substituted with one or more groups selected from 20 amino, mono- or di-alkyl amino, carboxy or optionally substituted heterocyclyl. or R¹⁵ and R¹⁶ together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring which optionally contains further heteroatoms.

Where one of R¹⁵ or R¹⁶ is hydrogen, examples of suitable heterocycls for the other include imidazole, imidazolinone, or tetrahydrothiophene-1,1-dioxide.

25 Preferably one of R¹⁵ or R¹⁶ is hydrogen and the other is optionally substituted alkyl, for example C₁₋₂ alkyl. Suitable substituents include one or more groups selected from amino, mono- or di-alkyl amino, a group NHSO₂R³⁰ where R³⁰ is methyl, carboxy or optionally substituted heterocyclyl, such as isoxazole optionally substituted mono or di-substituted with alkyl, such as methyl.

30 Where R¹⁵ and R¹⁶ together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring which optionally contains further heteroatoms, that

ring is, for example a morpholine ring. Alternatively, R⁴ is a group of sub-formula (IV) as listed above.

Alternatively, R⁴ is preferably a group (CH_t)_t where t is 1 and R¹⁷ is a group NR¹⁸R¹⁹. Particular examples of R¹⁸ and R¹⁹ include hydrogen and optionally substituted alkyl, or R¹⁸ and R¹⁹ together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring which optionally contains further heteroatoms, such as 5 pyrazole or tetrahydropyran. In particular, R¹⁸ and R¹⁹ together form a morpholine ring.

X is CH₂ or SO₂ and is preferably CH₂.

Suitable pharmaceutically acceptable salts of compounds of formula (I) include acid 10 addition salts such as methanesulfonate, fumarate, hydrochloride, hydrobromide, citrate, maleate and salts formed with phosphoric and sulphuric acid. In another aspect suitable salts are base salts such as an alkali metal salt for example sodium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, N-methylpiperidine, N-ethylpiperidine, procaine, dibenzylamine, N,N-dibenzylethylamine or 15 amino acids for example lysine. There may be more than one cation or anion depending on the number of charged functions and the valency of the cations or anions. A preferred pharmaceutically acceptable salt is a sodium salt.

An *in vivo* hydrolysable ester of a compound of the formula (I) containing carboxy or hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the 20 human or animal body to produce the parent acid or alcohol.

Suitable pharmaceutically acceptable esters for carboxy include alkyl esters, such as C₁₋₆ alkyl esters for example, ethyl esters, C₁₋₆alkoxymethyl esters for example methoxymethyl, C₁₋₆alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C₁₋₆cycloalkoxy-carbonyloxyC₁₋₆alkyl esters for example 25 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; and C₁₋₆alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.


Suitable pharmaceutically acceptable esters of compounds of formula (I) are *in vivo* 30 hydrolysable ester of a compound of the formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters and α -acyloxyalkyl ethers and related compounds which as a result of the *in vivo* hydrolysis of the ester breakdown to give the parent hydroxy

group. Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxymethoxy. A selection of *in vivo* hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxy carbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and 5 *N*-(dialkylaminoethyl)-*N*-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl.

Esters which are not *in vivo* hydrolysable are useful as intermediates in the production of the compounds of formula (I) and therefore these form a further aspect of the invention.

Thus examples of compounds of formula (I) include the following:

10

Table 1

15

Compd No.	R ³	R ⁴	R ⁵	R ⁶	R ^a	R ^b
1	H		H	H	Cl	Cl


2	H		H	H	Cl	Cl
3	H		H	H	Cl	Cl
4	H		H	H	Cl	Cl
5	H	CH ₂ N(CH ₃) ₂	OH	H	Cl	Cl
6	H	C(O)NH(CH ₂) ₂ N(CH ₃) ₂	H	H	Cl	Cl
7	H		H	H	Cl	Cl
8	H		H	H	Cl	Cl
9	H	C(O)NH(CH ₂) ₂ NHS(O) ₂ CH ₃	H	H	Cl	Cl
10	H		H	H	Cl	Cl
11	H		H	H	Cl	Cl

where * indicates the point of attachment of the group to the indole ring.

Yet a further aspect of the invention provides pharmaceutical compositions comprising a compound of formula (I) as defined above.

Compounds of formula (I) are suitably prepared by methods such as those described in International Patent Application Nos. PCT/GB98/02340 and PCT/GB98/02341.

In particular compounds of formula (I) can be prepared by reacting a compound of formula (VII)



5

(VII)

where X, R¹, R³, R⁵, R⁶ and R⁷ are as defined in relation to formula (I) and R^{2'} is a group R² as defined in relation to formula (I) or a protected form thereof, R⁴⁰ is a group C(O) or a group (CH₂)_t where t is as defined in relation to formula (I) and Z is a leaving group,
10 either (a) when R⁴⁰ is C(O), with a compound of formula (VIII)



(VIII)

where R¹⁵ and R¹⁶ are as defined in relation to formula (I);
or (b) where R⁴⁰ is group (CH₂)_t with a compound of formula (IX)

15




(IX)

where R¹⁷ is as defined in relation to formula (I);
and thereafter if necessary or desirable, deprotecting a group R^{2'} to a group R² or changing a
20 group R² to a different such group.

Suitable leaving groups for Z include halo such as chloro. The reaction is suitably effected in an organic solvent such as dichloromethane or tetrahydrofuran in the presence of a base such as triethylamine. Moderate temperatures, for example of from 0° to 50°C and conveniently ambient temperature may be employed.


The compounds of formula (VII) suitably have an ester group as R². Such compounds can then be converted to the corresponding acid by desterification, for example using sodium hydroxide in a mixture of methanol and tetrahydrofuran.

Compounds of formula (VII) where R⁴⁰ is C(O) are suitably prepared in situ by
5 reaction of the corresponding carboxylic acid with a halogenating agent such as oxalyl chloride. The acid is suitably derived from a compound of formula (X)



10 where X, R¹, R², R³, R⁵, R⁶ and R⁷ are as defined above, by a sequence of reactions in which the hydroxy methyl group is first converted to a carboxaldehyde for example by reaction with 2,3-dichloro-5,6-dicyanobenzoquinone, which is then oxidised to the corresponding acid using conventional methods.

Compounds of formula (X) are suitably prepared by reacting a compound of formula
15 (XI)



where X, R², R³, R⁵, R⁶ and R⁷ are as defined above and R⁴¹ is a protecting group, with a compound of formula (XII)

20 R¹-X-Z¹

(XII)

where R¹ and X are as defined in relation to formula (I) and Z¹ is a leaving group; and thereafter removing the protecting group R⁴¹.


Suitable leaving groups for Z¹ include halide such as chloride, bromide or iodide, as well as mesylate or tosylate. The reaction is suitably effected in an organic solvent such as 5 dimethylformamide (DMF) tetrahydrofuran (THF) or DCM in the presence of a base such as sodium hydride, sodium hydroxide, potassium carbonate. Optionally the reaction is effected in the presence of a suitable phase transfer catalyst. The choice of base and solvent is interdependent to a certain extent in that certain solvents are compatible with some bases only 10 as is understood in the art. For example, sodium hydride may preferably be used with dimethylformamide or tetrahydrofuran and sodium hydroxide is preferably used with dichloromethane and a phase transfer catalyst.

The reaction can be carried out at moderate temperatures, for example from 0 to 50°C and conveniently at about ambient temperature.

Preferably, R² is an ester group in the compound of formula IX and this may be 15 subsequently converted to an acid or to another ester or salt, by conventional methods later in the process.

Suitable protecting groups R⁴¹ include acetyl, benzyl or tetrahydropyranyl. The reaction conditions employed will be variable depending upon the nature of the protecting group R⁴⁰ and would be apparent to a skilled person. Acetyl groups may be removed by reaction with a 20 strong base such as sodium methoxide, whereas benzyl groups may be removed by hydrogenation, for example in the presence of a catalyst such as palladium catalyst. Removal of tetrahydropyranyl protecting groups may be effected using p-toluenesulphonic acid as illustrated hereinafter.


Compounds of formula (X) may be prepared by cyclisation of a compound of formula 25 (XIII)




where R^5 , R^6 , R^7 and R^{41} are as defined above and R^{42} and R^{43} represent a combination of moieties which can cyclise to form an appropriately substituted pyrrole ring. For example, R^{42} can be a group of formula $-CH=C(R^{44})N_3$, where R^{44} is a group R^2 as defined above, or a protected form thereof, and R^{43} may be hydrogen. Cyclisation to form a compound of formula (XII) may then be effected by heating for example under reflux in an organic solvent, in particular a high boiling aprotic solvent such as xylene or toluene.

Alternatively, R^{43} may be nitro and R^{42} may be a group of formula $-CH_2C(O)R^{2'}$ where $R^{2'}$ is as defined above in relation to formula (VII). These compounds will cyclise in the presence of a catalyst such as palladium on carbon in the presence of hydrogen. The reaction may be effected at moderate temperatures for example of from 0 to 80°C, conveniently at about ambient temperature.


Thus examples of compounds of formula (XIII) include compounds of formula (XIV) and (XV)





(XV)

5 Compounds of formula (XIII) where R^3 is hydrogen may be prepared for example by reacting a compound of formula (XVI)



(XVI)

10 with a compound of formula (XVII)



(XVII)

where R^5 , R^6 , R^7 , R^{41} , and R^2 are as defined hereinbefore. The reaction may be effected in an organic solvent such as ethanol at low temperatures of from -20 to 0°C, suitably at about 0°C.

15 The reaction is suitably effected in the presence of a base such as an alkoxide, in particular an ethoxide, for example potassium ethoxide.

Where necessary or desired, R^3 can be converted from hydrogen to a different group R^3 subsequently in the reaction scheme, using conventional methods.


Compounds of formula (XVII) are suitably prepared by reacting a compound of
20 formula (XVIII)



(XVIII)

where $\text{R}^{2'}$ is as defined above and R^{47} is a leaving group such as halide and in particular bromide, with an azide salt, such as an alkali metal azide salt in particular sodium azide.


5 Compounds of formula (XV) may be prepared by reacting a compound of formula (XIX)



(XIX)

where R^5 , R^6 , R^7 , R^3 , R^{40} and $\text{R}^{2'}$ are as defined above, with a compound of formula (XX)


10



(XX)

where $\text{R}^{2'}$ is as defined above and R^{48} leaving group such as hydroxy. Examples of
15 compounds of formula (XX) are oxalates such as diethyloxalate. The reaction is suitably
effected in the presence of a base such as sodium hydride in an organic solvent such as THF.
Moderate temperatures of from 0° to 40°C and conveniently ambient temperature is
employed.

Compounds of formula (VII) where R^{40} is $(\text{CH}_2)_t$ may be prepared by halogenation of a
20 compound of formula (XXI)



(XXI)

where t, R¹, R^{2'}, R³, R⁵, R⁶ and R⁷ are as defined above. Compound (X) above is a particular example of a compound of formula (XXI) and others may be prepared by analogous methods 5 to those described for formula (X).

Compounds of formula (XI), (XVI), (XVII), (XVIII), (XIX) and (XX) are either known compounds or they can be prepared from known compounds by conventional methods.

According to a further aspect of the invention there is provided a compound of the formula (I) as defined herein, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, for use in a method of treatment of the human or animal body by therapy. In 10 particular, the compounds are used in methods of treatment of inflammatory disease.

According to a further aspect of the present invention there is provided a method for antagonising an MCP-1 mediated effect in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a 15 compound of formula (I), or a pharmaceutically acceptable salt, or an *in vivo* hydrolysable ester thereof.

The invention also provides a compound of formula (I) as defined herein, or a pharmaceutically acceptable salt, or an *in vivo* hydrolysable ester thereof, for use as a medicament.

20 The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for 25 example as a finely divided powder) or for parenteral administration (for example as a sterile

aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).

The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended 5 for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.

Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding 10 agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the 15 gastrointestinal track, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.

Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.

20 Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxyethylene stearate), or 25 condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters 30 derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions

may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin). The oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

10 Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present.

15 The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these. Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavouring and preservative agents.

Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.

The pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above. A sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.

Suppository formulations may be prepared by mixing the active ingredient with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Suitable excipients include, for example, cocoa butter and polyethylene glycols.

5 Topical formulations, such as creams, ointments, gels and aqueous or oily solutions or suspensions, may generally be obtained by formulating an active ingredient with a conventional, topically acceptable, vehicle or diluent using conventional procedure well known in the art.

Compositions for administration by insufflation may be in the form of a finely divided
10 powder containing particles of average diameter of, for example, 30 μ or much less, the powder itself comprising either active ingredient alone or diluted with one or more physiologically acceptable carriers such as lactose. The powder for insufflation is then conveniently retained in a capsule containing, for example, 1 to 50mg of active ingredient for use with a turbo-inhaler device, such as is used for insufflation of the known agent sodium
15 cromoglycate.

Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets. Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently
20 arranged to dispense a metered quantity of active ingredient.

For further information on Formulation the reader is referred to Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

The amount of active ingredient that is combined with one or more excipients to
25 produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition. Dosage unit forms will
30 generally contain about 1 mg to about 500 mg of an active ingredient. For further information on Routes of Administration and Dosage Regimes the reader is referred to Chapter 25.3 in

Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

The size of the dose for therapeutic or prophylactic purposes of a compound of the Formula I will naturally vary according to the nature and severity of the conditions, the age 5 and sex of the animal or patient and the route of administration, according to well known principles of medicine. As mentioned above, compounds of the Formula I are useful in treating diseases or medical conditions which are due alone or in part to the effects of farnesylation of rats.

In using a compound of the Formula I for therapeutic or prophylactic purposes it will 10 generally be administered so that a daily dose in the range, for example, 0.5 mg to 75 mg per kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous administration, a dose in the range, for example, 0.5 mg to 30 mg per kg body weight will generally be used. Similarly, for administration by inhalation, a dose in the range, for 15 example, 0.5 mg to 25 mg per kg body weight will be used. Oral administration is however preferred.

The invention is further illustrated, but not limited by the following Examples in which the following general procedures were used unless stated otherwise.

20 **Preparation 1**

Ethyl N-(3,4-dichlorobenzyl)-4-(2-tetrahydropyranloxy)methylindole-2-carboxylate

Ethyl-4-(2-tetrahydropyranloxy)methylindole-2-carboxylate (5.1 g) (Chung-gi Shen et al., Heterocycles, 43, 1996, 891-898) and sodium hydride (741 mg, 60% in mineral oil) were stirred in DMF (100 ml) under argon at ambient temperature for 20 minutes. 3,4-

25 Dichlorobenzyl chloride (2.79 ml) was added and the mixture stirred overnight, then partitioned between ethyl acetate (150 ml) and water (150 ml). The organic phase was washed with water (2 x 150 ml), dried ($MgSO_4$), concentrated *in vacuo* and the residue purified by column chromatography using *iso*-hexane, then ethyl acetate : *iso*-hexane (5/95) as eluent to give the product as a yellow oil (4.39 g, 56%); NMR δ ($CDCl_3$) 1.40 (t, 3H), 1.50 - 2.00 (m, 6H), 3.60 (m, 1H), 4.00 (m, 1H), 4.35 (q, 2H), 4.75 (m, 1H), 4.85 (d, 1H), 5.10 (d, 1H), 5.80 (s, 2H), 6.85 (m, 1H), 7.15 - 7.40 (m, 5H), 7.50 (s, 1H); M/z (+) 462.5 (MH^+).

Preparation 2**Ethyl N-(3,4-dichlorobenzyl)-4-hydroxymethylindole-2-carboxylate**

Ethyl *N*-(3,4-dichlorobenzyl)-4-(2-tetrahydropyranyloxy)methylindole-2-carboxylate (4.38 g) and *p*-toluenesulphonic acid (100 mg) in ethanol (100 ml) was stirred at ambient temperature for 3 hours, then concentrated *in vacuo* and the residue dissolved in ethyl acetate (100 ml), washed with water (100 ml), dried (MgSO_4) and concentrated to give the product as an off-white solid (3.22 g, 90%); NMR δ (CD_3SOCD_3) 1.25 (t, 3H), 4.25 (q, 2H), 4.80 (d, 2H), 5.20 (m, 1H), 5.80 (s, 2H), 6.85 (m, 1H), 7.10 (d, 1H), 7.30 (m, 2H), 7.50 (m, 3H); M/z (+) 378.3 ($M\text{H}^+$).

10

Preparation 3**Ethyl 4-formyl-N-(3,4-dichlorobenzyl)indole-2-carboxylate**

Ethyl *N*-(3,4-dichlorobenzyl)-4-hydroxymethylindole-2-carboxylate (5.17 g) and 2,3-dichloro-5,6-dicyanobenzoquinone (3.10 g) were stirred in dioxane (100 ml) at ambient temperature, overnight. The reaction mixture was concentrated *in vacuo* and the residue dissolved in dichloromethane (100 ml) and filtered. The filtrate was concentrated *in vacuo* and the residue purified by column chromatography using 10% ethyl acetate : *iso*-hexane as eluent to give product as a yellow solid (4.88 g, 95%); NMR δ (CD_3SOCD_3) 1.30 (t, 3H), 4.30 (q, 2H), 5.90 (s, 2H), 6.85 (m, 1H), 7.90 (m, 1H), 8.00 (m, 1H), 10.22 (s, 1H); M/z (+) 376.3 (20) ($M\text{H}^+$).

Preparation 4***N*-(3,4-Dichlorobenzyl)-2-ethoxycarbonylindole-4-carboxylic acid**

A solution of sodium chlorite (9.70 g) and sodium dihydrogen orthophosphate (13.02 g) in water (50 ml) was added dropwise to a solution of ethyl 4-formyl-*N*-(3,4-dichlorobenzyl)indole-2-carboxylate (4.47 g) and 2-methylbut-2-ene (50 ml) in *tert*-butyl alcohol (100 ml) and the mixture stirred for 72 hours at ambient temperature, then concentrated *in vacuo* and the resulting precipitate was filtered and dried to give the product as an off-white solid (4.16 g, 89%); NMR δ (CD_3SOCD_3) 1.25 (t, 3H), 4.30 (q, 2H), 5.85 (s, 2H), 6.85 (m, 1H), 7.35 (m, 1H), 7.40 (q, 1H), 7.50 (m, 1H), 7.80 (m, 3H); M/z (-) 390.1 ($M\text{H}^+$).

Preparation 5**Ethyl 4-chloromethyl-N-(3,4-dichlorobenzyl)indole-2-carboxylate**

Ethyl *N*-(3,4-dichlorobenzyl)-4-hydroxymethylindole-2-carboxylate (0.89 g). dimethylformamide (0.5 ml) and thionyl chloride (189 µl) in dichloromethane (40 ml) were 5 stirred at ambient temperature overnight and the resulting precipitate was filtered and dried *in vacuo* to give the product as a white solid (0.62 g, 67%); NMR δ (CD₃SOCD₃) 1.30 (t, 3H), 4.30 (q, 2H), 5.10 (s, 2H), 5.85 (s, 2H), 6.90 (m, 1H), 7.30 (m, 3H), 7.55 (m, 3H); M/z (+) 396.2 (MH⁺).

10 **Preparation 6****Ethyl 5-hydroxyindole-2-carboxylate**

Boron tribromide (64.58 g) was added dropwise to a stirred solution of ethyl 5-methoxyindole-2-carboxylate (20 g) in dry dichloromethane (1000 ml) at -78°C under an atmosphere of argon. The reaction was allowed to warm to room temperature and stirred for a 15 further 2 hours. The reaction was poured into ice / saturated aqueous sodium hydrogen carbonate solution with stirring and extracted with ethyl acetate. Combined organic extracts were washed with saturated aqueous sodium hydrogen carbonate solution, water, aqueous saturated sodium chloride solution and dried (MgSO₄). The solution was concentrated *in vacuo* and the residue was purified by column chromatography using 0 - 60% diethyl ether ; 20 *iso*-hexane as eluent to give product as a white solid (9.02 g, 48%); NMR δ (CD₃SOCD₃) 1.31 (t, 3H), 4.29 (q, 2H), 6.79 (dd, 1H), 6.90 (dd, 1H), 7.22 (d, 1H), 8.84 (s, 1H), 11.52 (brs, 1H); M/z (+) 206 (MH⁺).

Preparation 725 **Ethyl 5-acetoxyindole-2-carboxylate**

A stirred solution of ethyl 5-hydroxyindole-2-carboxylate (7.79 g) and DMAP (20 mg) in acetic anhydride (80 ml) was heated at 80°C for 4 hours. The reaction was concentrated *in vacuo* and the residue was dissolved in ethyl acetate. Combined organic extracts were washed with hydrochloric acid (2.0 M), saturated aqueous sodium hydrogen carbonate solution, water, 30 aqueous saturated sodium chloride solution and dried (MgSO₄). The solution was concentrated *in vacuo* to give the product as a yellow solid (9.39 g, 100 %); NMR δ

(CD₃SOCD₃) 1.20 (t, 3H), 2.10 (s, 3H), 4.19 (q, 2H), 6.86 (dd, 1H), 6.97 (d, 1H), 7.20 (s, 1H), 7.29 (d, 1H); *M/z* (+) 248 (*MH*⁺).

Preparation 8

5 Ethyl 5-acetoxy-N-(3,4-dichlorobenzyl)indole-2-carboxylate

3,4-Dichlorobenzyl bromide (5.96 g) was added to a stirred solution of ethyl 5-acetoxyindole-2-carboxylate (5.4 g) and potassium carbonate (6.94 g) in acetonitrile (500 ml) under an atmosphere of argon. The reaction was heated at 80°C for 16 hours, then concentrated *in vacuo* and the residue partitioned between ethyl acetate and water. Combined organic extracts were washed with water, saturated aqueous sodium chloride and dried (MgSO₄). The solvent was removed *in vacuo* and the residue was triturated with *iso*-hexane to give the product as a cream solid (5.55 g, 63%); NMR δ (CD₃SOCD₃) 1.27 (t, 3H), 2.27 (s, 3H), 4.28 (q, 2H), 5.82 (s, 2H), 6.90 (d, 1H), 7.09 (dd, 1H), 7.33 - 7.40 (m, 2H), 7.46 (d, 1H) 7.52 (d, 1H), 7.60 (d, 1H).

15

Preparation 9

Ethyl N-(3,4-dichlorobenzyl)-5-hydroxyindole-2-carboxylate

Sodium ethoxide (1.86 g) was added to a stirred solution of ethyl 5-acetoxy-N-(3,4-dichlorobenzyl)indole-2-carboxylate (5.55 g) in ethanol (50 ml) under an atmosphere of argon. The reaction was stirred at room temperature for 2 hours, then concentrated *in vacuo* and the residue acidified with aqueous hydrochloric acid (2.0 M) and extracted with dichloromethane. Combined organic extracts were washed with water, saturated aqueous sodium chloride solution and dried (MgSO₄). The solvent was removed *in vacuo* and the residue was triturated with hexane / diethyl ether to give the product as a white solid (3.17 g, 92%); NMR δ (CD₃SOCD₃) 1.26 (t, 3H), 4.25 (q, 2H), 5.75 (s, 2H), 6.81 - 6.91 (m, 2H), 6.98 (d, 1H), 7.19 (s, 1H), 7.29 (d, 1H), 7.38 (d, 1H) 7.50 (d, 1H), 9.06 (s, 1H); *M/z* (+) 364 (*MH*⁺).

Example 1

Compound 1 ethyl ester

30 *N*-(3,4-Dichlorobenzyl)-2-ethoxycarbonylindole-4-carboxylic acid (100 mg), DMF (1 drop) and a solution of oxalyl chloride in dichloromethane (2M, 140 µl) were stirred in dichloromethane (4 ml) under argon, at ambient temperature, for 7 hours. The reaction mixture was concentrated *in vacuo* and dissolved in dichloromethane (4 ml). 3-amino-

tetrahydrothiophene-1,1-dioxide (69 mg) and triethylamine (71 μ l) were added and the reaction stirred under argon, overnight. The reaction mixture was diluted with dichloromethane (20 ml), washed with aq. 2M HCl (30 ml) and water (30 ml), dried ($MgSO_4$), concentrated *in vacuo* and the residue purified by column chromatography using ethyl acetate : iso-hexane (gradient 25/75-100/0) as eluent to give the product as an off-white solid (73 mg, 56%). M/z (+) 509.3 (MH^+).

Example 2

The procedure described in Example 1 above was repeated using the appropriate amine. Thus 10 were obtained the compounds described below.

Compound 4 ethyl ester

48% yield; M/z (+) 461.5 (MH^+).

15 **Compound 2 ethyl ester**

96% yield; M/z (+) 500.4 (MH^+).

Compound 3 ethyl ester

60% yield; M/z (+) 509.3 (MH^+).

20

Compound 6 ethyl ester

63% yield; M/z (+) 462.2 (MH^+).

Compound 7 ethyl ester

25 72% yield; M/z (+) 503.2 (MH^+).

Compound 8 ethyl ester

51% yield; M/z (+) 500.2 (MH^+).

30 **Compound 9 ethyl ester**

13% yield; M/z (+) 512.1 (MH^+).

Example 3**Compound 10 ethyl methyl diester**

15 *N*-(3,4-Dichlorobenzyl)-2-ethoxycarbonylindole-4-carboxylic acid (150 mg), *L*-histidine methyl ester dihydrochloride (93 mg), 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (123 mg) and triethylamine (107 µl) were stirred in dichloromethane (15 ml) at ambient temperature, overnight. The reaction mixture was concentrated *in vacuo* and the residue purified by column chromatography using ethyl acetate : *iso*-hexane (gradient 10/90 - 100/0) then 10% methanol : ethyl acetate as eluent to give product as a white gum (35 mg, 17%); *M/z* (+) 543.2 (*MH*⁺).

10

Example 4**Compound 4**

15 Compound 4 ethyl ester (50 mg) was dissolved in tetrahydrofuran (2 ml). Aqueous sodium hydroxide (2M, 2 ml) and methanol (1 ml) were added and the mixture stirred at ambient temperature for 2 hours, then concentrated *in vacuo* and the residue dissolved in water (4 ml), acidified with acetic acid and resulting precipitate filtered, washed with water and dried *in vacuo* to give the product as a white solid (19mg, 40%); NMR δ (CD₃SOCD₃) 3.30 - 3.90 (m, 8H), 6.00 (s, 2H), 7.05 (m, 1H), 7.20 (m, 2H), 7.40 (t, 1H), 7.50 (m, 1H), 7.60 (m, 1H), 7.70 (m, 1H); *M/z* (-) 431.4 (*M-H*⁺).

20

Example 5

The procedure described in Example 4 above was repeated using the appropriate ester. Thus were obtained the compounds described below.

25 **Compound 1**

77% yield; NMR δ (CD₃SOCD₃) 2.20 (m, 1H), 3.05 - 3.60 (m, 5H), 4.70 (m, 1H), 5.90 (s, 2H), 6.90 (m, 1H), 7.30 (m, 2H), 7.50 (m, 2H), 7.60 (s, 1H), 7.70 (m, 1H), 8.70 (d, 1H); *M/z*(-) 481.3 (*M-H*⁺).

30

Compound 2

90% yield; NMR δ (CD₃SOCD₃) 2.20 (s, 3H), 2.40 (s, 3H), 4.20 (d, 2H), 6.00 (s, 2H), 7.00 (m, 1H), 7.20 (t, 1H), 7.35 (m, 3H), 7.50 (m, 1H), 7.55 (m, 1H), 8.60 (t, 1H); *M/z* (-) 470.1 (M-H⁺).

Compound 3

53% yield; *M/z* (-) 479.1 (M-H⁺).

10 Compound 6

81% yield; NMR δ (CD₃SOCD₃) 2.40 (m, 6H), 2.75 (m, 2H), 3.45 (m, 2H), 5.85 (s, 2H), 6.85 (m, 1H), 7.25 (m, 2H), 7.45 (m, 2H), 7.60 (m, 2H), 8.35 (m, 1H); *M/z* (-) 432.2 (M-H⁺).

Compound 7

15 98% yield; NMR δ (CD₃SOCD₃) 3.22 (m, 2H), 3.40 (m, 2H), 5.90 (s, 2H), 6.23 (s, 1H), 6.90 (m, 1H), 7.30 (m, 2H), 7.50 (m, 2H), 7.65 (m, 2H), 8.40 (m, 1H); *M/z* (-) 473.2 (M-H⁺).

Compound 8

100% yield; *M/z* (-) 470.2 (M-H⁺).

20

Compound 9

85% yield; NMR δ (CD₃SOCD₃) 2.90 (s, 3H), 3.15 (m, 2H), 3.40 (m, 2H), 5.95 (s, 2H), 6.90 (m, 1H), 7.15 (m, 1H), 7.30 (m, 2H), 7.50 (m, 2H), 7.60 (m, 1H), 7.65 (m, 1H), 8.40 (m, 1H); *M/z* (-) 482.4 (M-H⁺).

25

Compound 10

51% yield; *M/z* (-) 499.1 (M-H⁺).

Compound 11

30 50% yield; NMR δ (CD₃SOCD₃) 2.40 (m, 4H), 3.50 (m, 4H), 3.70 (s, 2H), 5.85 (s, 2H), 6.90 (m, 1H), 7.05 (m, 1H), 7.20 (m, 1H), 7.30 - 7.60 (m, 4H); *M/z* (-) 417.2 (M-H⁺).

Example 6**Compound 11 ethyl ester**

Ethyl 4-chloromethyl-*N*-(3,4-dichlorobenzyl)indole-2-carboxylate (150 mg), 5 morpholine (50 µl) and triethylamine (106 µl) in tetrahydrofuran (5 ml) were stirred at ambient temperature for 4 days, then concentrated *in vacuo*. The residue was dissolved in ethyl acetate (30 ml), washed with water (30 ml), dried (MgSO_4), and concentrated *in vacuo*. The crude residue was triturated with toluene and the resulting white solid filtered and dried (79 mg, 47%); NMR δ (CDCl_3) 1.42 (t, 3H), 2.98 (m, 2H), 3.37 (m, 2H), 3.95 (m, 2H), 4.20 - 10 4.60 (m, 6H), 5.80 (s, 2H), 6.90 (m, 1H), 7.20 (m, 1H), 7.25 - 7.60(m, 4H), 7.70 (m, 1H); M/z (+) 447.3 ($M\text{H}^+$).

Example 7**Ethyl *N*-(3,4-dichlorobenzyl)-4-dimethylaminomethyl-5-hydroxyindole-2-carboxylate****15 (Ethyl ester of Compound 5)**

To a stirred solution of ethyl *N*-(3,4-dichlorobenzyl)-5-hydroxyindole-2-carboxylate (2.1 g) in ethanol (50 ml) was added successively aqueous dimethylamine (40%, 0.5 ml) and aqueous formaldehyde (0.5 ml). The solution was allowed to stand overnight and the resulting crystals filtered and dried *in vacuo* to give the product as pale yellow crystals (1.7 g, 20 70%); NMR δ (CD_3SOCD_3) 1.24 (t, 3H), 2.23 (s, 6H), 3.81 (s, 2H), 4.24 (q, 2H), 5.75 (s, 2H), 6.82 (d, 1H), 6.90 (dd, 1H), 7.30 (m, 3H), 7.50 (d, 1H); M/z (+) 423, 421 ($M\text{H}^+$), 378, 376.

Example 8***N*-(3,4-Dichlorobenzyl)-4-dimethylaminomethyl-5-hydroxyindole-2-carboxylic acid****25 (Compound 5)**

Using the method of Example 5, the ester from Example 7 was converted to the title compound.

72% yield; NMR δ (CD_3SOCD_3) 2.43 (s, 6H), 4.04 (s, 2H), 5.85 (s, 2H), 6.78 (d, 1H), 7.00 (dd, 1H), 7.18 (s, 1H), 7.22 (d, 1H), 7.34 (s, 1H), 7.42 (d, 1H); M/z (+) 393, 391 ($M\text{H}^+$), 348, 30 347.

Example 9

Biological Assays for hMCP-1 AntagonistsBiological Testing.

The following biological test methods, data and Examples serve to illustrate the present invention.

5 Abbreviations:

ATCC	American Type Culture Collection, Rockville, USA.
BCA	Bicinchoninic acid, (used, with copper sulphate, to assay protein)
BSA	Bovine Serum Albumin
DMEM	Dulbecco's modified Eagle's medium
EGTA	Ethylenbis(oxyethylenenitrilo)tetraacetic acid
FCS	Foetal calf serum
HEPES	(N-[2-Hydroxyethyl]piperazine-N'-[2-ethanesulphonic acid])
HBSS	Hank's Balanced Salt Solution
hMCP-1	Human Monocyte Chemoattractant Protein-1
PBS	Phosphate buffered saline
PCR	Polymerase chain reaction

AMPLITAQ™, available from Perkin-Elmer Cetus, is used as the source of thermostable DNA polymerase.

Binding Buffer is 50 mM HEPES, 1 mM CaCl₂, 5 mM MgCl₂, 0.5% foetal calf serum, adjusted to pH 7.2 with 1 M NaOH.

10 Non-Essential Amino Acids (100X concentrate) is: L-Alanine, 890 mg/l; L-Asparagine, 1320 mg/l; L-Aspartic acid, 1330 mg/l; L-Glutamic acid, 1470 mg/l; Glycine, 750 mg/l; L-Proline, 1150 mg/l and; L-Serine, 1050 mg/l.

Hypoxanthine and Thymidine Supplement (50x concentrate) is: hypoxanthine, 680 mg/l and; thymidine, 194 mg/l.

15 Penicillin-Streptomycin is: Penicillin G (sodium salt); 5000 units/ml; Streptomycin sulphate, 5000 µg/ml.

Human monocytic cell line THP-1 cells are available from ATCC, accession number ATCC TIB-202.

Hank's Balanced Salt Solution (HBSS) was obtained from Gibco; see *Proc. Soc. Exp. Biol. Med.*, 1949, 71, 196.

Synthetic cell culture medium. RPMI 1640 was obtained from Gibco; it contains inorganic salts [Ca(NO₃)₂.4H₂O 100 mg/l; KCl 400 mg/l; MgSO₄.7H₂O 100 mg/l; NaCl 6000 mg/l; NaHCO₃ 2000 mg/l & Na₂HPO₄ (anhyd) 800 mg/l], D-Glucose 2000 mg/l, reduced glutathione 1 mg/l, amino acids and vitamins.

5 FURA-2/AM is 1-[2-(5-carboxyoxazol-2-yl)-6-aminobenzofuran-5-oxy]-2-(2'-amino-5'-methylphenoxy)-ethane-N,N,N',N'-tetraacetic acid pentaacetoxymethyl ester and was obtained from Molecular Probes, Eugene, Oregon, USA.

Blood Sedimentation Buffer contains 8.5g/l NaCl and 10g/l hydroxyethyl cellulose.

Lysis Buffer is 0.15M NH₄Cl⁻, 10mM KHCO₃, 1mM EDTA

10 Whole Cell Binding Buffer is 50 mM HEPES, 1 mM CaCl₂, 5 mM MgCl₂, 0.5% BSA, 0.01% NaN₃, adjusted to pH 7.2 with 1M NaOH.

Wash buffer is 50mM HEPES, 1mM CaCl₂, 5mM MgCl₂, 0.5% heat inactivated FCS, 0.5MNaCl adjusted to pH7.2 with 1M NaOH.

General molecular biology procedures can be followed from any of the methods described in "Molecular Cloning - A Laboratory Manual" Second Edition, Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory, 1989).

i) Cloning and expression of hMCP-1 receptor

The MCP-1 receptor B (CCR2B) cDNA was cloned by PCR from THP-1 cell RNA using suitable oligonucleotide primers based on the published MCP-1 receptor sequences (Charo *et al.*, 1994, *Proc. Natl. Acad. Sci. USA*, 91, 2752). The resulting PCR products were cloned into vector PCR-II™ (InVitrogen, San Diego, CA.). Error free CCR2B cDNA was subcloned as a Hind III-Not I fragment into the eukaryotic expression vector pCDNA3 (InVitrogen) to generate pCDNA3/CC-CKR2A and pCDNA3/CCR2B respectively.

Linearised pCDNA3/CCR2B DNA was transfected into CHO-K1 cells by calcium phosphate precipitation (Wigler *et al.*, 1979, *Cell*, 16, 777). Transfected cells were selected by the addition of Geneticin Sulphate (G418, Gibco BRL) at 1mg/ml, 24 hours after the cells had been transfected. Preparation of RNA and Northern blotting were carried out as described previously (Needham *et al.*, 1995, *Prot. Express. Purific.*, 6, 134). CHO-K1 clone 7 (CHO-CCR2B) was identified as the highest MCP-1 receptor B expressor.

30 ii) Preparation of membrane fragments

CHO-CCR2B cells were grown in DMEM supplemented with 10% foetal calf serum, 2 mM glutamine, 1x Non-Essential Amino Acids, 1x Hypoxanthine and Thymidine

Supplement and Penicillin-Streptomycin (at 50 µg streptomycin/ml, Gibco BRL). Membrane fragments were prepared using cell lysis/differential centrifugation methods as described previously (Siciliano *et al.*, 1990, *J. Biol. Chem.*, **265**, 19658). Protein concentration was estimated by BCA protein assay (Pierce, Rockford, Illinois) according to the manufacturer's
5 instructions.

iii) Assay

¹²⁵I MCP-1 was prepared using Bolton and Hunter conjugation (Bolton *et al.*, 1973, *Biochem. J.*, **133**, 529; Amersham International plc]. Equilibrium binding assays were carried out using the method of Ernst *et al.*, 1994, *J. Immunol.*, **152**, 3541. Briefly, varying amounts
10 of ¹²⁵I-labeled MCP-1 were added to 7µg of purified CHO-CCR2B cell membranes in 100 µl of Binding Buffer. After 1 hour incubation at room temperature the binding reaction mixtures were filtered and washed 5 times through a plate washer (Brandel MLR-96T Cell Harvester) using ice cold Binding Buffer. Filter mats (Brandel GF/B) were pre-soaked for 60 minutes in
0.3% polyethylenimine prior to use. Following filtration individual filters were separated into
15 3.5ml tubes (Sarstedt No. 55.484) and bound ¹²⁵I-labeled MCP-1 was determined (LKB 1277 Gammamaster). Cold competition studies were performed as above using 100 pM ¹²⁵I-labeled MCP-1 in the presence of varying concentrations of unlabelled MCP-1. Non-specific binding was determined by the inclusion of a 200-fold molar excess of unlabelled MCP-1 in the reaction.

20 Ligand binding studies with membrane fragments prepared from CHO-CCR2B cells showed that the CCR2B receptor was present at a concentration of 0.2 pmoles/mg of membrane protein and bound MCP-1 selectively and with high affinity ($IC_{50} = 110$ pM, $K_d = 120$ pM). Binding to these membranes was completely reversible and reached equilibrium after 45 minutes at room temperature, and there was a linear relationship between MCP-1
25 binding and CHO-CCR2B cell membrane concentration when using MCP-1 at concentrations between 100 pM and 500 pM.

Test compounds dissolved in DMSO (5µl) were tested in competition with 100 pM labelled MCP-1 over a concentration range (0.01-50µM) in duplicate using eight point dose-response curves and IC_{50} concentrations were calculated.

30 Compounds tested of the present invention had IC_{50} values of 50µM or less in the hMCP-1 receptor binding assay described herein.

b) MCP-1 mediated calcium flux in THP-1 cells

The human monocytic cell line THP-1 was grown in a synthetic cell culture medium RPMI 1640 supplemented with 10 % foetal calf serum, 6mM glutamine and Penicillin-Streptomycin (at 50 µg streptomycin/ml, Gibco BRL). THP-1 cells were washed in HBSS (lacking Ca²⁺ and Mg²⁺) + 1 mg/ml BSA and resuspended in the same buffer at a 5 density of 3 x 10⁶ cells/ml. The cells were then loaded with 1mM FURA-2/AM for 30 min at 37°C, washed twice in HBSS, and resuspended at 1x10⁶ cells/ml. THP-1 cell suspension (0.9 ml) was added to a 5 ml disposable cuvette containing a magnetic stirrer bar and 2.1 ml of prewarmed (37°C) HBSS containing 1 mg/ml BSA, 1 mM MgCl₂ and 2 mM CaCl₂. The cuvette was placed in a fluorescence spectrophotometer (Perkin Elmer, Norwalk, CT) and 10 preincubated for 4 min at 37°C with stirring. Fluorescence was recorded over 70 sec and cells were stimulated by addition of hMCP-1 to the cuvette after 10 sec. [Ca²⁺]i was measured by excitation at 340 nm and 380 nm alternately and subsequent measurement of the intensity of the fluorescence emission at 510 nm. The ratio of the intensities of the emitted fluorescent light following excitation at 340 nm and 380 nm, (R), was calculated and displayed to give 15 and estimate of cytoplasmic [Ca²⁺] according to the equation:-

$$[\text{Ca}^{2+}]_i = K_d \frac{(R - R_{\min})}{(R_{\max} - R)}$$

where the K_d for FURA-2 Ca²⁺ complex at 37°C was taken to be 224nm. R_{max} is the maximal fluorescence ratio determined after addition of 10 mM Ionomycin, R_{min} is the minimal ratio 20 determined by the subsequent addition of a Ca²⁺ free solution containing 5 mM EGTA, and Sf2/Sb2 is the ratio of fluorescence values at 380 nm excitation determined at R_{min} and R_{max}, respectively.

Stimulation of THP-1 cells with hMCP-1 induced a rapid, transient rise in [Ca²⁺]i in a specific and dose dependent manner. Dose response curves indicated an approximate EC₅₀ of 25 2 nm. Test compounds dissolved in DMSO (10µl) were assayed for inhibition of calcium release by adding them to the cell suspension 10 sec prior to ligand addition and measuring the reduction in the transient rise in [Ca²⁺]i. Test compounds were also checked for lack of agonist activity by addition in place of hMCP-1.

c) hMCP-1 and RANTES mediated chemotaxis.

30 In vitro chemotaxis assays were performed using the human monocytic cell line THP-1. Cell migration through polycarbonate membranes was measured by enumerating those passing through either directly by Coulter counting or indirectly by use of a

colourimetric viability assay measuring the cleavage of a tetrazolium salt by the mitochondrial respiratory chain (Scudiero D.A. *et al.* 1988, *Cancer Res.*, **48**, 4827-4833).

Chemoattractants were introduced into a 96-well microtitre plate which forms the lower well of a chemotaxis chamber fitted with a PVP-free 5 µm poresize polycarbonate adhesive framed filter membrane (NeuroProbe MB series, Cabin John, MD 20818, USA) according to the manufacturer's instructions. The chemoattractant was diluted as appropriate in synthetic cell culture medium, RPMI 1640 (Gibco) or supplemented with 2 mM glutamine and 0.5% BSA, or alternatively with HBSS with Ca²⁺ and Mg²⁺ without Phenol Red (Gibco) plus 0.1% BSA. Each dilution was degassed under vacuum for 30 min and was placed (400 µl) in the lower wells of the chamber and THP-1 cells (5x10⁵ in 100 µl RPMI 1640 + 0.5%BSA) were incubated in each well of the upper chamber. For the inhibition of chemotaxis the chemoattractant was kept at a constant submaximal concentration determined previously (1nM MCP-1) and added to the lower well together with the test compounds dissolved in DMSO (final DMSO concentration < 0.05% v/v) at varying concentrations. The chamber was incubated for 2 h at 37°C under 5 % CO₂. The medium was removed from the upper wells which were then washed out with 200 µl physiological saline before opening the chamber, wiping dry the membrane surface and centrifuging the 96-well plate at 600 g for 5 min to harvest the cells. Supernatant (150 µl) was aspirated and 10 µl of cell proliferation reagent, WST-1, {4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-phenyl disulfonate} plus an electron coupling reagent (Boehringer Mannheim, Cat.no. 1644 807) was added back to the wells. The plate was incubated at 37°C for 3 h and the absorbance of the soluble formazan product was read on a microtitre plate reader at 450 nm. The data was input into a spreadsheet, corrected for any random migration in the absence of chemoattractant and the average absorbance values, standard error of the mean, and significance tests were calculated. hMCP-1 induced concentration dependent cell migration with a characteristic biphasic response, maximal 0.5-1.0 nm.

In an alternative form of the above assay, fluorescently tagged cells can be used in order to assist in end point detection. In this case, the THP-1 cells used are fluorescently tagged by incubation in the presence of 5mM Calcein AM (Glycine, N,N'-[[3',6'-bis(acetoxy)-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthene]-2',7'-diyl]bis(methylene)] bis[N-[2-[(acetoxy)methoxy]-2-oxoethyl]]-bis[(acetoxy)methyl] ester; Molecular Probes) for 45 minutes in the dark. Cells are harvested by centrifugation and resuspended in HBSS

(without Phenol Red) with Ca^{2+} , Mg^{2+} and 0.1% BSA. 50 μl (2×10^5 cells) of the cell suspension are placed on the filter above each well and, as above, the unit is incubated at 37°C for 2 hours under 5% CO₂. At the end of the incubation, cells are washed off the upper face of the filter with phosphate buffered saline, the filter removed from the plate and the number of 5 cells attracted to either the underside of the filter or the lower well estimated by reading fluorescence at 485nm excitation, 538nm emission wavelengths (fmax, Molecular Devices). The data was input into a spreadsheet, corrected for any random migration in the absence of chemoattractant and the average fluorescence values, standard error of the mean, percentage inhibition and IC₅₀ of compounds under test and significance tests can be calculated. In 10 addition to MCP-1 induced chemotaxis, this alternative form of the assay was also used to measure inhibition of RANTES (2nM) induced chemotaxis.

d) Binding to human peripheral blood mononuclear cells(PBMCs)

i) Preparation of human PBMCs

Fresh human blood (200ml) was obtained from volunteer donors, collected into 15 sodium citrate anticoagulant to give a final concentration of 0.38%. The blood was mixed with Sedimentation Buffer and incubated at 37°C for 20 minutes. The supernatant was collected and centrifuged at 1700rpm for 5 minutes (Sorvall RT6000D). The pellet obtained was resuspended in 20 ml RPMI/BSA (1mg/ml) and 4 x 5mls of cells were carefully layered over 4 x 5mls of Lymphoprepä (Nycomed) in 15ml centrifuge tubes. Tubes were spun at 20 1700rpm for 30 minutes (Sorvall RT6000D) and the resultant layer of cells was removed and transferred to 50ml Falcon tubes. The cells were washed twice in Lysis Buffer to remove any remaining red blood cells followed by 2 washes in RPMI/BSA. Cells were resuspended in 5mls of Binding Buffer. Cell number was measured on a Coulter counter and additional binding buffer was added to give a final concentration of 1.25×10^7 PBMCs /ml.

ii) Assay

[¹²⁵I]MCP-1 was prepared using Bolton and Hunter conjugation (Bolton *et al.*, 1973, *Biochem. J.*, **133**, 529; Amersham International plc]. Equilibrium binding assays were carried out using the method of Ernst *et al.*, 1994, *J. Immunol.*, **152**, 3541. Briefly, 50 μl of ¹²⁵I-labeled MCP-1 (final concentration 100pM) was added to 40 μl (5×10^5 cells) of cell suspension in a 96 30 well plate. Compounds, diluted in Whole Cell Binding Buffer from a stock solution of 10mM in DMSO were added in a final volume of 5 μl to maintain a constant DMSO concentration in the assay of 5%. Total binding was determined in the absence of compound. Non-specific

binding was defined by the addition of 5 μ l cold MCP-1 to give a final assay concentration of 100nM. Assay wells were made up to a final volume of 100 μ l with Whole Cell Binding Buffer and the plates sealed. Following incubation at 37°C for 60 minutes the binding reaction mixtures were filtered and washed for 10 seconds using ice cold Wash Buffer using a plate washer (Brandel MLR-96T Cell Harvester). Filter mats (Brandel GF/B) were pre-soaked for 60 minutes in 0.3% polyethylenimine plus 0.2% BSA prior to use. Following filtration individual filters were separated into 3.5ml tubes (Sarstedt No. 55.484) and bound 125 I-labeled MCP-1 was determined (LKB 1277 Gammamaster).

Test compound potency was determined by assay in duplicate using six point dose-response curves and IC₅₀ concentrations were determined.

Compounds tested of the present invention had IC₅₀ values of less than 5 μ M in the hMCP-1 receptor binding assay described herein. For example compound 9 had an IC₅₀ of 0.64 μ M.

No physiologically unacceptable toxicity was observed at the effective dose for compounds tested of the present invention.

Example 10

Pharmaceutical Compositions

The following Example illustrates, but is not intended to limit, pharmaceutical dosage forms of the invention as defined herein (the active ingredient being termed "Compound X"). for therapeutic or prophylactic use in humans:

(a)

Tablet I	mg/tablet
Compound X.	100
Lactose Ph.Eur	182.75
Croscarmellose sodium	12.0
Maize starch paste (5% w/v paste)	2.25
Magnesium stearate	3.0

(b)

<u>Tablet II</u>	<u>mg/tablet</u>
Compound X	50
Lactose Ph.Eur	223.75
Croscarmellose sodium	6.0
Maize starch	15.0
Polyvinylpyrrolidone (5% w/v paste)	2.25
Magnesium stearate	3.0

(c)

<u>Tablet III</u>	<u>mg/tablet</u>
Compound X	1.0
Lactose Ph.Eur	93.25
Croscarmellose sodium	4.0
Maize starch paste (5% w/v paste)	0.75
Magnesium stearate	1.0

5

(d)

<u>Capsule</u>	<u>mg/capsule</u>
Compound X	10
Lactose Ph.Eur	488.5
Magnesium	1.5

(e)

<u>Injection I</u>	<u>(50 mg/ml)</u>
Compound X	5.0% w/v
1M Sodium hydroxide solution	15.0% v/v
0.1M Hydrochloric acid	to adjust pH to 7.6
Polyethylene glycol 400	4.5% w/v
Water for injection	to 100%

(f)

<u>Injection II</u>	(10 mg/ml)
Compound X	1.0% w/v
Sodium phosphate BP	3.6% w/v
0.1M Sodium hydroxide solution	15.0% v/v
Water for injection	to 100%

(g)

<u>Injection III</u>	(1mg/ml, buffered to pH6)
Compound X	0.1% w/v
Sodium phosphate BP	2.26% w/v
Citric acid	0.38% w/v
Polyethylene glycol 400	3.5% w/v
Water for injection	to 100%

5

(h)

<u>Aerosol I</u>	<u>mg/ml</u>
Compound X	10.0
Sorbitan trioleate	13.5
Trichlorofluoromethane	910.0
Dichlorodifluoromethane	490.0

(i)

<u>Aerosol II</u>	<u>mg/ml</u>
Compound X	0.2
Sorbitan trioleate	0.27
Trichlorofluoromethane	70.0
Dichlorodifluoromethane	280.0
Dichlorotetrafluoroethane	1094.0

(j)

<u>Aerosol III</u>	<u>mg/ml</u>
Compound X	2.5
Sorbitan trioleate	3.38
Trichlorofluoromethane	67.5
Dichlorodifluoromethane	1086.0
Dichlorotetrafluoroethane	191.6

(k)

<u>Aerosol IV</u>	<u>mg/ml</u>
Compound X	2.5
Soya lecithin	2.7
Trichlorofluoromethane	67.5
Dichlorodifluoromethane	1086.0
Dichlorotetrafluoroethane	191.6

(l)

<u>Ointment</u>	<u>ml</u>
Compound X	40 mg
Ethanol	300 µl
Water	300 µl
1-Dodecylazacycloheptan-2-one	50 µl
Propylene glycol	to 1 ml

5


Note:

Compound X in the above formulation may comprise a compound illustrated in Examples 1 to 6 herein. The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate. The aerosol formulations (h)-(k) may be used in conjunction with standard, metered dose aerosol dispensers, and the suspending agents sorbitan trioleate and soya lecithin may be replaced by

an alternative suspending agent such as sorbitan monooleate, sorbitan sesquioleate, polysorbate 80, polyglycerol oleate or oleic acid.

Claims

1. A compound of formula (I)




5

(I)

X is CH₂ or SO₂

R¹ is an optionally substituted aryl or heteroaryl ring;

10 R² is carboxy, cyano, -C(O)CH₂OH, -CONHR⁸, -SO₂NHR⁹, tetrazol-5-yl, SO₃H, or a group of formula (VI)



(VI)

where R⁸ is selected from hydrogen, alkyl, aryl, cyano, hydroxy, -SO₂R¹² where R¹² is alkyl,

15 aryl, heteroaryl, or haloalkyl, or R⁸ is a group-(CHR¹³)-COOH where r is an integer of 1-3 and each R¹³ group is independently selected from hydrogen or alkyl; R⁹ is hydrogen, alkyl, optionally substituted aryl such as optionally substituted phenyl or optionally substituted heteroaryl such as 5 or 6 membered heteroaryl groups, or a group COR¹⁴ where R¹⁴ is alkyl, aryl, heteroaryl or haloalkyl; R¹⁰ and R¹¹ are independently selected from hydrogen or alkyl,

20 particularly C₁₋₄ alkyl;

R³ is hydrogen, a functional group, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocyclyl,

optionally substituted alkoxy, optionally substituted aralkyl, optionally substituted aralkyloxy, optionally substituted cycloalkyl;

R⁴ is a group C(O)NR¹⁵R¹⁶ or a group (CH₂)_nR¹⁷ ;

where R¹⁵ and R¹⁶ are independently selected from hydrogen, optionally substituted alkyl,

5 optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl or optionally substituted heterocyclyl provided that R¹⁵ and R¹⁶ are not both hydrogen, or R¹⁵ and R¹⁶ together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring which optionally contains further heteroatoms;

R¹⁷ is selected from NR¹⁸R¹⁹, OR²⁰ or S(O)_sR²¹

10 where R¹⁸ and R¹⁹ are independently selected from hydrogen, optionally substituted hydrocarbyl or optionally substituted heterocyclyl, or R¹⁸ and R¹⁹ together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring which optionally contains further heteroatoms;

R²⁰ is substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl,

15 optionally substituted cycloalkyl or optionally substituted heterocyclyl,

R²¹ is optionally substituted hydrocarbyl or optionally substituted heterocyclyl,

s is 0, 1 or 2 and t is an integer of from 1-4;


R⁵, R⁶ and R⁷ are independently selected from hydrogen, a functional group or an optionally substituted hydrocarbyl groups or optionally substituted heterocyclyl groups,

20 or a pharmaceutically acceptable salt, *in vivo* hydrolysable ester, or amide of the compound of formula (I).

2. A compound according to claim 1 where R⁴ is a group C(O)NR¹⁵R¹⁶ where one of R¹⁵ or R¹⁶ is hydrogen or alkyl and the other is optionally substituted heterocyclyl or optionally substituted alkyl, or R¹⁵ and R¹⁶ together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring which optionally contains further heteroatoms.

3. A compound according to claim 2 wherein R⁴ is a group C(O)NR¹⁵R¹⁶ where one of R¹⁵ or R¹⁶ is hydrogen and the other is heterocyclyl or alkyl substituted with one or more groups selected from amino, mono- or di-alkyl amino, carboxy or optionally substituted heterocyclyl.

4. A compound according to claim 2 wherein R⁴ is a group C(O)NR¹⁵R¹⁶ and R¹⁵ and R¹⁶ together with the nitrogen atom to which they are attached form a morpholine ring, or R⁴ is a group of sub-formula (IV)



5

5. A compound according to claim 1 wherein R⁴ is preferably a group (CH₂)_tR¹⁷ where t is 1 and R¹⁷ is a group NR¹⁸R¹⁹ and R¹⁸ and R¹⁹ are as defined in claim 1.

10

6. A compound according to any one of the preceding claims wherein R¹ is 3,4-dichlorophenyl, 3-fluoro-4-chlorophenyl, 3-chloro-4-fluorophenyl or 2,3-dichloropyrid-5-yl.


7. A compound according to any one of the preceding claims wherein X is CH₂.

15

8. A pharmaceutical composition comprising a compound according to any one of the preceding claims in combination with a pharmaceutically acceptable carrier.

9. A compound according to any one of claims 1 to 7 for use in the preparation of a medicament for use in the treatment of inflammatory disease.

20 10. A method of making a compound of formula (I) as defined in claim 1 which method comprises reacting a compound of formula (VII)



25

(VII)

where X, R¹, R³, R⁵, R⁶ and R⁷ are as defined in relation to formula (I) and R² is a group R² as defined in relation to formula (I) or a protected form thereof, R⁴⁰ is a group C(O) or a group (CH₂)_t where t is as defined in relation to formula (I) and Z is a leaving group, either (a) when R⁴⁰ is C(O), with a compound of formula (VIII)

5 **HNR¹⁵R¹⁶**
(VIII)

where R^{15} and R^{16} are as defined in relation to formula (I);

or (b) where R⁴⁰ is group (CH₂)_i with a compound of formula (IX)

HR¹⁷

10 (IX)

where R^{17} is as defined in relation to formula (I);

and thereafter if necessary or desirable, deprotecting a group R² to a group R¹ or changing a group R² to a different such group.

15

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/GB 00/00271

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07D209/42 C07D401/06 C07D401/12 A61K31/40 A61K31/44
 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO 99 07678 A (ZENECA LIMITED) 18 February 1999 (1999-02-18) the whole document	1-10
P,A	WO 99 07351 A (ZENECA LIMITED) 18 February 1999 (1999-02-18) cited in the application the whole document	1-10
A	WO 98 06703 A (WARNER-LAMBERT COMPANY) 19 February 1998 (1998-02-19) page 1 -page 9, line 5	1-10
A	WO 96 37469 A (MERCK FROSST CANADA INC.) 28 November 1996 (1996-11-28) page 72 -page 89; claims 1-18	1-10
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the International filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the International search report

11 May 2000

18/05/2000

Name and mailing address of the ISA

Authorized officer

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Kyriakakou, G

INTERNATIONAL SEARCH REPORTInt'l Application No
PCT/GB 00/00271**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 37467 A (MERCK FROSST CANADA) 28 November 1996 (1996-11-28) page 119 -page 141; claims 1-18	1-10
A	WO 96 18393 A (SMITHKLINE BEECHAM CORPORATION) 20 June 1996 (1996-06-20) page 40 -page 46; claims 1-18	1-10
A	US 5 081 145 A (YVAN GUINDON ET AL.) 14 January 1992 (1992-01-14) the whole document	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No	
PCT/GB 00/00271	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9907678 A	18-02-1999	AU	8638098 A	01-03-1999
WO 9907351 A	18-02-1999	AU NO	8638198 A 20000573 A	01-03-1999 04-02-2000
WO 9806703 A	19-02-1998	AU EP	4054197 A 0927167 A	06-03-1998 07-07-1999
WO 9637469 A	28-11-1996	US AU CA	5604253 A 5683296 A 2219111 A	18-02-1997 11-12-1996 28-11-1996
WO 9637467 A	28-11-1996	US AU CA	5639780 A 5683096 A 2219155 A	17-06-1997 11-12-1996 28-11-1996
WO 9618393 A	20-06-1996	US AU EP JP ZA	5684032 A 4514496 A 0800389 A 10510538 T 9510535 A	04-11-1997 03-07-1996 15-10-1997 13-10-1998 14-08-1996
US 5081145 A	14-01-1992	NONE		